產品中心 / 埃克替尼
鹽酸埃克替尼上市後，深入推進臨床研究，助力中國肺癌研究走上國際舞台，開展了90多項學術研究，包括一線治療研究、肺癌伴腦轉移研究、EGFR狀態不明患者研究、EGFR21外顯子敏感突變加量研究、與化療聯合的研究等，發表SCI論文200多篇，影響因數700多分，並在ASCO、WCLC、ESMO等國際學術會議上報告、展示。
鹽酸埃克替尼改變了我國晚期肺癌治療指南，樹立了一線治療標準，形成了埃克替尼在晚期非小細胞肺癌臨床應用的專家共識，被納入MIMS《惡性腫瘤用藥指南》、國家衛生計劃生育委員會2018《中國原發性肺癌診療規范》、CSCO2019原發性肺癌診療指南、衛健委《2019腫瘤用藥指南原則》等。
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
- First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
- Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study
- Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
- A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
- Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
